{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T10:25:01Z","timestamp":1752229501589,"version":"3.37.3"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T00:00:00Z","timestamp":1755993600000},"content-version":"am","delay-in-days":357,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","brachyjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.brachy.2024.06.001","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T15:44:34Z","timestamp":1722008674000},"page":"559-568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of perioperative and subacute postoperative complications between LDR and HDR monotherapy brachytherapy for prostate cancer"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7897-3721","authenticated-orcid":false,"given":"Peter L.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Ruth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2299-7767","authenticated-orcid":false,"given":"Douglas Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Hallman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Y.T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica Karen","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres F.","family":"Correa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iavor","family":"Veltchev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teh","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3231-2565","authenticated-orcid":false,"given":"Xiaoming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8989-4095","authenticated-orcid":false,"given":"Joseph","family":"Panetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kutikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2187-317X","authenticated-orcid":false,"given":"Eric M.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2024.06.001_bib0001","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.brachy.2024.06.001_bib0002","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2011.10827.x","volume":"109","author":"Grimm","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.brachy.2024.06.001_bib0003","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.urology.2010.07.539","article-title":"Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer","volume":"77","author":"Zelefsky","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.brachy.2024.06.001_bib0004","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1038\/s41598-022-09120-0","article-title":"Comparison of toxicities between ultrahypofractionated radiotherapy versus brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer","volume":"12","author":"Yamazaki","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.brachy.2024.06.001_bib0005","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2024.06.001_bib0006","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijrobp.2017.05.013","article-title":"Long-term results of a randomized trial comparing iridium implant plus external beam radiation therapy with external beam radiation therapy alone in node-negative locally advanced cancer of the prostate","volume":"99","author":"Dayes","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2024.06.001_bib0007","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2018.0587","article-title":"Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9-10 prostate cancer","volume":"319","author":"Kishan","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.brachy.2024.06.001_bib0008","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijrobp.2016.07.013","article-title":"Prostate brachytherapy case volumes by academic and nonacademic practices: implications for future residency training","volume":"96","author":"Orio","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2024.06.001_bib0009","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1002\/cncr.28697","article-title":"The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base","volume":"120","author":"Martin","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.brachy.2024.06.001_bib0010","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.brachy.2011.12.012","article-title":"A survey of current clinical practice in permanent and temporary prostate brachytherapy: 2010 update","volume":"11","author":"Buyyounouski","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2024.06.001_bib0011","doi-asserted-by":"crossref","first-page":"320","DOI":"10.5114\/jcb.2019.86974","article-title":"Treatment patterns of high-dose-rate and low-dose-rate brachytherapy as monotherapy for prostate cancer","volume":"11","author":"Barnes","year":"2019","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.brachy.2024.06.001_bib0012","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0360-3016(99)00499-X","article-title":"Palladium-103 brachytherapy for prostate carcinoma","volume":"46","author":"Blasko","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2024.06.001_bib0013","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.ijrobp.2010.01.005","article-title":"Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy","volume":"79","author":"Taira","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2024.06.001_bib0014","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.brachy.2011.05.011","article-title":"Biochemical and clinical experience with real-time intraoperatively planned permanent prostate brachytherapy","volume":"11","author":"Lubbe","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2024.06.001_bib0015","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/01.ju.0000113299.34404.22","article-title":"High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds","volume":"171","author":"Grills","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2024.06.001_bib0016","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ijrobp.2015.07.2290","article-title":"High-Dose-Rate Monotherapy for Localized Prostate Cancer: 10-Year Results","volume":"94","author":"Hauswald","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2024.06.001_bib0017","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.meddos.2016.06.002","article-title":"Dosimetric and radiobiological comparison of volumetric modulated arc therapy, high-dose rate brachytherapy, and low-dose rate permanent seeds implant for localized prostate cancer","volume":"41","author":"Yang","year":"2016","journal-title":"Med Dosim"},{"key":"10.1016\/j.brachy.2024.06.001_bib0018","doi-asserted-by":"crossref","first-page":"196","DOI":"10.5603\/RPOR.a2021.0028","article-title":"Comparative dosimetrical analysis of intensity-modulated arc therapy, cyberknife therapy and image-guided interstitial HDR and LDR brachytherapy of low risk prostate cancer","volume":"26","author":"Fr\u00f6hlich","year":"2021","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.brachy.2024.06.001_bib0019","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/COC.0000000000000796","article-title":"Patient-reported quality of life after SBRT, LDR, and HDR brachytherapy for prostate cancer: a comparison of outcomes","volume":"44","author":"Paly","year":"2021","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.brachy.2024.06.001_bib0020","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.adro.2018.10.004","article-title":"Transitioning from a low-dose-rate to a high-dose rate prostate brachytherapy program: comparing initial dosimetry and improving workflow efficiency through targeted interventions","volume":"4","author":"Solanki","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.brachy.2024.06.001_bib0021","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.adro.2019.04.003","article-title":"A phase 2 randomized pilot study comparing high-dose-rate brachytherapy and low-dose-rate brachytherapy as monotherapy in localized prostate cancer","volume":"4","author":"Hathout","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.brachy.2024.06.001_bib0022","doi-asserted-by":"crossref","first-page":"e1234","DOI":"10.1097\/PTS.0000000000000670","article-title":"A systematic review of methods for medical record analysis to detect adverse events in hospitalized patients","volume":"17","author":"Klein","year":"2021","journal-title":"J Patient Saf"},{"key":"10.1016\/j.brachy.2024.06.001_bib0023","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.brachy.2023.06.003","article-title":"A dosimetric analysis of rectal hydrogel spacer use in patients with recurrent prostate cancer undergoing salvage high-dose-rate brachytherapy","volume":"22","author":"Lee","year":"2023","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2024.06.001_bib0024","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.brachy.2009.08.004","article-title":"An intraoperative real-time sleeved seed technique for permanent prostate brachytherapy","volume":"9","author":"Sharma","year":"2009","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2024.06.001_bib0025","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.brachy.2017.07.013","article-title":"Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: a comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time","volume":"16","author":"Kollmeier","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2024.06.001_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109672","article-title":"Salvage prostate brachytherapy in radiorecurrent prostate cancer: an international Delphi consensus study","volume":"184","author":"Corkum","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2024.06.001_bib0027","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ijrobp.2008.05.022","article-title":"Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients","volume":"73","author":"Keyes","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2024.06.001_bib0028","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijrobp.2017.09.050","article-title":"Prospective phase 2 trial of permanent seed implantation prostate brachytherapy for intermediate-risk localized prostate cancer: efficacy, toxicity, and quality of life outcomes","volume":"100","author":"Frank","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2024.06.001_bib0029","first-page":"64","article-title":"Single fraction of HDR brachytherapy for prostate cancer: results of the SiFEPI phase II prospective trial","volume":"37","author":"Hannoun-Levi","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.brachy.2024.06.001_bib0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.radonc.2020.09.007","article-title":"Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: outcomes from two clinical trials with and without an MRI-guided boost","volume":"154","author":"Alayed","year":"2021","journal-title":"Radiother Oncol"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472124000771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472124000771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T02:44:13Z","timestamp":1728528253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472124000771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1538472124000771"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2024.06.001","relation":{},"ISSN":["1538-4721"],"issn-type":[{"type":"print","value":"1538-4721"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of perioperative and subacute postoperative complications between LDR and HDR monotherapy brachytherapy for prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2024.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Brachytherapy Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}